| Literature DB >> 22679115 |
Margaret A Tempero1, J Pablo Arnoletti, Stephen W Behrman, Edgar Ben-Josef, Al B Benson, Ephraim S Casper, Steven J Cohen, Brian Czito, Joshua D I Ellenhorn, William G Hawkins, Joseph Herman, John P Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Wen Wee Ma, Mokenge P Malafa, Nipun B Merchant, Sean J Mulvihill, Peter Muscarella, Eric K Nakakura, Jorge Obando, Martha B Pitman, Aaron R Sasson, Anitra Tally, Sarah P Thayer, Samuel Whiting, Robert A Wolff, Brian M Wolpin, Deborah A Freedman-Cass, Dorothy A Shead.
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.Entities:
Mesh：
Year: 2012 PMID： 22679115 PMCID： PMC3807091 DOI： 10.6004/jnccn.2012.0073
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908